{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3775, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "product_demo", "function": "present_solution", "notes": "Includes study design details for a multicenter, randomized, double-blind, placebo-controlled trial.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/13", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-13", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 14, "from": 7, "beatId": "fc2a383c-968e-4c6a-836f-347c2e1bb09a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 7-14 detail the solution, including DA-1241 and its competitive differentiation", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a diagram to map the drug's mechanism of action to specific biological effects in the liver, pancreas, and immune system.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/14", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-14", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 14, "from": 7, "beatId": "fc2a383c-968e-4c6a-836f-347c2e1bb09a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 7-14 detail the solution, including DA-1241 and its competitive differentiation", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/15", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-15", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 20, "from": 15, "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The table highlights DA-1726's dual agonist mechanism (GLP-1R/GCGR) as a key differentiator against standard GLP-1 agonists.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/16", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-16", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 20, "from": 15, "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a hub-and-spoke diagram to illustrate the systemic effects of the hormone.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/17", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-17", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 20, "from": 15, "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses preclinical data to demonstrate efficacy superiority over a market-leading GLP-1 agonist.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/18", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-18", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 20, "from": 15, "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses three distinct chart types to demonstrate efficacy and metabolic impact.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/19", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-19", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 20, "from": 15, "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "appendix_methodology", "function": "present_framework", "notes": "Includes definitions for MAD, SAD, PK, PD, FPFV, and LPLV.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/20", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-20", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 20, "from": 15, "beatId": "3fbd2aa2-3e57-4d4f-b65f-ea90e59c9f1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Slides 15-20 discuss the therapeutic potential of DA-1726 in obesity", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/21", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-21", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes footnotes regarding anti-dilution provisions and reverse stock split/warrant conversion context.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/22", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-22", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/23", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-23", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/24", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-24", "loopMatches": [ { "to": 24, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e", "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)", "position": 1, "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b515-770b-a5e9-c449fc01e3f7", "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "closing_ask", "function": "state_next_steps", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/25", "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7", "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Features a 3D rendering of a synapse.", "imagePath": "https://imgproxy.kitesheet.com/tRpvqQASDG7X-8yxKqkdicVPWxlRm4jKMmB8JKZSIt4/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lNWYzNDE5OGFmZjQwODBmMjY4N2ZlNTY5Y2FmZjRjMC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/1", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/Apf-gINbshmBzKa3woYv3CPZDKMPlglKvL6JkpuYE8Y/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lNWYzNDE5OGFmZjQwODBmMjY4N2ZlNTY5Y2FmZjRjMC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/zPZTE95TkBnfQwkg5kOMsow4pwoHy_2IU5OKShLiOJI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lNWYzNDE5OGFmZjQwODBmMjY4N2ZlNTY5Y2FmZjRjMC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/aoRssYLEqGaEx5M0N3qAbNq9IyOplN_qOrTO5y0dmqw/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lNWYzNDE5OGFmZjQwODBmMjY4N2ZlNTY5Y2FmZjRjMC9wMDAxLnBuZw" }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/2", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/3", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a standard pharmaceutical pipeline visualization (Discovery to NDA).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/4", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "problem_statement", "function": "frame_problem", "notes": "Includes a personal testimonial/case study image of a patient (Shay) to humanize the disease.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/5", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 5, "beatId": "07446762-8c93-42f3-9372-d09450c844ce", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "The document identifies ALS as a debilitating disease with limited treatment options (p5).", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a biological mechanism-of-action illustration to show how the drug components interact with specific cellular stressors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/6", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a combination of a biological mechanism diagram and a pharmacokinetic line chart to prove efficacy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/7", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "traction", "function": "show_traction", "notes": "Includes a process diagram for iPSC generation and two charts: a survival curve and a hazard ratio bar chart.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/8", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "solution", "function": "present_solution", "notes": "The chart demonstrates that PrimeC aligns the peak concentrations of two different drugs, which is the core value proposition of their formulation technology.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/9", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "traction", "function": "show_traction", "notes": "Study identifier NST002, 15 patients, open-label, intermediate formulation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/10", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "Includes details on screen failures and co-treatment with Riluzole.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/11", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "appendix_methodology", "function": "present_framework", "notes": "Uses numbered icons for primary/secondary and a lightbulb icon for exploratory.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/12", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "appendix_methodology", "function": "analyze_data", "notes": "Includes a footnote citation for the methodology definitions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/13", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "appendix_methodology", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/14", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide shows baseline characteristics for a clinical trial, confirming that the treatment and placebo groups are well-matched.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/15", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "traction", "function": "show_traction", "notes": "The table displays percentages for various categories of adverse events (AEs) and treatment-emergent adverse events (TEAEs).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/16", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "traction", "function": "show_traction", "notes": "The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) for the ITT population in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/17", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "context", "function": "establish_context", "notes": "The slide uses icons to represent functional domains and provides specific clinical examples of what a 1-point change means for patient quality of life.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/18", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-18", "loopMatches": [ { "to": 20, "from": 18, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "876b6a16-52fc-4c73-87b1-9f5a8addd6c3", "evidence": "The document highlights the significant impact of losing or keeping a single point on the ALSFRS-R and the loss of physical functions in ALS patients (p18-20).", "position": 0, "objective": "What is the cost of not treating ALS patients effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 18, "beatId": "73151b50-5273-46dd-8e73-1aea2f3b3ecc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the significant impact of losing or keeping a single point on the ALSFRS-R and the loss of physical functions in ALS patients (p18-20).", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "traction", "function": "show_traction", "notes": "The chart visualizes the reduction in point loss, highlighting the efficacy of PrimeC.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/19", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-19", "loopMatches": [ { "to": 20, "from": 18, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "876b6a16-52fc-4c73-87b1-9f5a8addd6c3", "evidence": "The document highlights the significant impact of losing or keeping a single point on the ALSFRS-R and the loss of physical functions in ALS patients (p18-20).", "position": 0, "objective": "What is the cost of not treating ALS patients effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 18, "beatId": "73151b50-5273-46dd-8e73-1aea2f3b3ecc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the significant impact of losing or keeping a single point on the ALSFRS-R and the loss of physical functions in ALS patients (p18-20).", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a human silhouette to categorize ALS symptoms into four domains, then presents bar charts for each domain comparing treatment vs placebo.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/20", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-20", "loopMatches": [ { "to": 20, "from": 18, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "876b6a16-52fc-4c73-87b1-9f5a8addd6c3", "evidence": "The document highlights the significant impact of losing or keeping a single point on the ALSFRS-R and the loss of physical functions in ALS patients (p18-20).", "position": 0, "objective": "What is the cost of not treating ALS patients effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 18, "beatId": "73151b50-5273-46dd-8e73-1aea2f3b3ecc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the significant impact of losing or keeping a single point on the ALSFRS-R and the loss of physical functions in ALS patients (p18-20).", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "traction", "function": "show_traction", "notes": "The chart highlights a 17.2% attenuation in the decline of SVC scores for the PrimeC group compared to placebo.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/21", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a series of blue blocks to represent different research pillars/methodologies within the PARADIGM trial.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/22", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "comparison_table", "function": "cite_precedent", "notes": "The slide uses a case study to validate the business model of combination therapies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/23", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/24", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 24, "beatId": "607e443a-68d1-4a02-ab22-3e7aadef1c04", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "The document highlights PrimeC's strong clinical and commercial potential (p24).", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "traction", "function": "show_traction", "notes": "The slide presents clinical biomarker data comparing control vs AD groups across 6 different markers, using Mann-Whitney U tests for significance.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/25", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide outlines the RoAD study parameters including patient population, dosing, and primary/secondary endpoints.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/26", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "team_bio", "function": "other", "notes": "The slide uses a grid layout to display five key advisors with their respective credentials and logos of their affiliated institutions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/27", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "other", "function": "other", "notes": "The slide uses a grid layout to present institutional and corporate partners.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/28", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "timeline", "function": "plan_implementation", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/29", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "closing_ask", "function": "state_next_steps", "notes": "Slide 30 of the deck.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/30", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-30", "loopMatches": [ { "to": 30, "from": 30, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "1cd0e582-d9cf-49b2-8fba-17009006f23c", "evidence": "The document presents PrimeC's potential for a quick win in ALS treatment (p30).", "position": 1, "objective": "What is the potential for PrimeC to provide a quick win in ALS treatment?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "traction", "function": "show_traction", "notes": "The chart shows a clear divergence between the treatment and placebo arms over time, with a 29.2% difference at the 180-day mark.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/31", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "traction", "function": "show_traction", "notes": "The chart shows a divergence in SVC decline between the treatment and placebo groups over time.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/32", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b5af-740f-a5f5-cc716fe64761", "docSlug": "e5f34198aff4080f2687fe569caff4c0", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data includes adjusted means, 95% confidence intervals, p-values, and percentage differences for various motor and respiratory domains.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/33", "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761", "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/QDXab7w40UL4JeLwS9qqXs89AY83_5WSGzYmVkc5428/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83N2IxYjkyYjMzNDE0ZTYxOGFmZDU1YTUwYzZjMzliZi9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/1", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/SNiXvEF4kfOPFGA0lAcCqoqzTq-WTBE8IWyRJhomE7s/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83N2IxYjkyYjMzNDE0ZTYxOGFmZDU1YTUwYzZjMzliZi9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/6URJzV5xhl1QtCZHTeNttptN8Q4EPtIq2jRCRS4-vOM/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83N2IxYjkyYjMzNDE0ZTYxOGFmZDU1YTUwYzZjMzliZi9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/z75Yvgol_DbHxnjzfIb3EQ6uNBh57TiqwNSefr5_OA4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83N2IxYjkyYjMzNDE0ZTYxOGFmZDU1YTUwYzZjMzliZi9wMDAxLnBuZw" }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/2", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 3, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/3", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-3", "loopMatches": [ { "to": 4, "from": 3, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "260af7ae-09de-42c3-a5fb-ed25efad8db7", "evidence": "The document presents key takeaways and actions to strengthen risk management", "position": 0, "objective": "Highlighting the company's accomplishments and actions to strengthen risk management", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 4, "from": 3, "beatId": "22658a9a-f799-4f3d-9cb6-266b394a55f5", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document highlights the company's accomplishments and actions to strengthen risk management", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 4, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/4", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-4", "loopMatches": [ { "to": 4, "from": 3, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "260af7ae-09de-42c3-a5fb-ed25efad8db7", "evidence": "The document presents key takeaways and actions to strengthen risk management", "position": 0, "objective": "Highlighting the company's accomplishments and actions to strengthen risk management", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.7, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 4, "from": 3, "beatId": "22658a9a-f799-4f3d-9cb6-266b394a55f5", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document highlights the company's accomplishments and actions to strengthen risk management", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 5, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The table compares NYCB's performance at two different dates (9/30/22 and 12/31/23) against a peer median as of 9/30/23.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/5", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 6, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a three-row layout to categorize key financial metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/6", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-6", "loopMatches": [ { "to": 20, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02562f21-e10e-416f-9ef6-4bfc05b7a419", "evidence": "The document provides detailed financial information and comparisons to peers", "position": 1, "objective": "Discussing the financial implications of not taking actions to strengthen risk management", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 6, "beatId": "9ad011d9-6bc3-498d-adfb-6582a82f6b3d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides detailed financial information, including income comparisons and balance sheet highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 7, "slideType": "comparison_table", "function": "analyze_data", "notes": "Includes non-GAAP reconciliations note and rounding note.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/7", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-7", "loopMatches": [ { "to": 20, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02562f21-e10e-416f-9ef6-4bfc05b7a419", "evidence": "The document provides detailed financial information and comparisons to peers", "position": 1, "objective": "Discussing the financial implications of not taking actions to strengthen risk management", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 6, "beatId": "9ad011d9-6bc3-498d-adfb-6582a82f6b3d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides detailed financial information, including income comparisons and balance sheet highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 8, "slideType": "comparison_table", "function": "analyze_data", "notes": "Includes non-GAAP adjustments and profitability metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/8", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-8", "loopMatches": [ { "to": 20, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02562f21-e10e-416f-9ef6-4bfc05b7a419", "evidence": "The document provides detailed financial information and comparisons to peers", "position": 1, "objective": "Discussing the financial implications of not taking actions to strengthen risk management", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 6, "beatId": "9ad011d9-6bc3-498d-adfb-6582a82f6b3d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides detailed financial information, including income comparisons and balance sheet highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 9, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Includes footnotes explaining specific line items and non-GAAP metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/9", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-9", "loopMatches": [ { "to": 20, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02562f21-e10e-416f-9ef6-4bfc05b7a419", "evidence": "The document provides detailed financial information and comparisons to peers", "position": 1, "objective": "Discussing the financial implications of not taking actions to strengthen risk management", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 6, "beatId": "9ad011d9-6bc3-498d-adfb-6582a82f6b3d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides detailed financial information, including income comparisons and balance sheet highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 10, "slideType": "kpi_overview", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/10", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-10", "loopMatches": [ { "to": 20, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02562f21-e10e-416f-9ef6-4bfc05b7a419", "evidence": "The document provides detailed financial information and comparisons to peers", "position": 1, "objective": "Discussing the financial implications of not taking actions to strengthen risk management", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 6, "beatId": "9ad011d9-6bc3-498d-adfb-6582a82f6b3d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides detailed financial information, including income comparisons and balance sheet highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 11, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide uses two pie charts to illustrate deposit diversification and risk profile.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/11", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-11", "loopMatches": [ { "to": 20, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02562f21-e10e-416f-9ef6-4bfc05b7a419", "evidence": "The document provides detailed financial information and comparisons to peers", "position": 1, "objective": "Discussing the financial implications of not taking actions to strengthen risk management", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 6, "beatId": "9ad011d9-6bc3-498d-adfb-6582a82f6b3d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides detailed financial information, including income comparisons and balance sheet highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 12, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart illustrates the bridge between two balance sheet dates.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/12", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-12", "loopMatches": [ { "to": 20, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02562f21-e10e-416f-9ef6-4bfc05b7a419", "evidence": "The document provides detailed financial information and comparisons to peers", "position": 1, "objective": "Discussing the financial implications of not taking actions to strengthen risk management", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 6, "beatId": "9ad011d9-6bc3-498d-adfb-6582a82f6b3d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides detailed financial information, including income comparisons and balance sheet highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 13, "slideType": "comparison_table", "function": "analyze_data", "notes": "The chart highlights Flagstar's positive growth (+6.79%) against negative trends in the broader US banking sector.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/13", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-13", "loopMatches": [ { "to": 20, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02562f21-e10e-416f-9ef6-4bfc05b7a419", "evidence": "The document provides detailed financial information and comparisons to peers", "position": 1, "objective": "Discussing the financial implications of not taking actions to strengthen risk management", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 6, "beatId": "9ad011d9-6bc3-498d-adfb-6582a82f6b3d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides detailed financial information, including income comparisons and balance sheet highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b693-702c-9006-89e388a5cfbb", "docSlug": "77b1b92b33414e618afd55a50c6c39bf", "documentTitle": "New York Community Bancorp | Results Presentation Deck | 42 slides", "authorId": "new-york-community-bancorp", "authorName": "New York Community Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.2938006, "pageNumber": 14, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The table compares NYCB (as of Dec 31, 2023) against industry benchmarks (as of Sept 30, 2023).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b693-702c-9006-89e388a5cfbb/14", "deckHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb", "deckAnchorHref": "/decks/019de076-b693-702c-9006-89e388a5cfbb#slide-14", "loopMatches": [ { "to": 20, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02562f21-e10e-416f-9ef6-4bfc05b7a419", "evidence": "The document provides detailed financial information and comparisons to peers", "position": 1, "objective": "Discussing the financial implications of not taking actions to strengthen risk management", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 6, "beatId": "9ad011d9-6bc3-498d-adfb-6582a82f6b3d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides detailed financial information, including income comparisons and balance sheet highlights", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }